IRCT20200509047364N1招募中2 期
Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients
Bandare-abbas University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 65 years（—）
- 性别
- All
入选标准
- •All definitively positive COVID-19 patients with Hb=9.
- •Having at least one of the severe symptoms of COVID-19, including tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 =93 saturation, the partial pressure ratio of arterial oxygen <300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100
排除标准
- •Patients with a history of coagulopathy
- •Patients with a history of thrombosis
- •Patients with a history of deep vein thrombosis
- •Patients with a history of chronic lung disease
- •Patients with a history of diabetes mellitus
- •Patients with weakened immune systems
- •Patients with a history of end stage renal disease
- •Patients with liver disease
- •Patients with a history of taking oral contraceptive pills (OCPs)
- •Patients with systolic blood pressure greater than 160 mmHg
- •Patients with diastolic blood pressure greater than 90 mmHg
- •Patients over 65 years of age
- •Patients with erythropoietin above 500
- •Patients with a history of myocardial infarction or unstable angina
- •Patients with a history of malignancy
研究者
相似试验
已完成
不适用
Investigation on efficacy and safety of combination treatment with imidafenacin and mirabegron in patients with overactive bladder.overactive bladderJPRN-UMIN000016236Clinical Research Support Center Kyushu30
招募中
4 期
STOP HZ Studyrheumatoid arthritisJPRN-jRCTs031230329Kaneko Yuko60
已完成
2 期
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcomasoft tissue cancer10072990NL-OMON39691Morphotek, Inc10
进行中（未招募）
1 期
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.EUCTR2012-001399-12-NLMorphotek Inc.200
进行中（未招募）
1 期
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.Metastatic Soft Tissue SarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001399-12-BEMorphotek Inc.200